[go: up one dir, main page]

Kimura et al., 2010 - Google Patents

Barminomycin, a model for the development of new anthracyclines

Kimura et al., 2010

View PDF
Document ID
1958065046256525731
Author
Kimura K
Spencer D
Bilardi R
Swift L
Box A
Brownlee R
Cutts S
Phillips D
Publication year
Publication venue
Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents)

External Links

Snippet

Barminomycin is a member of the anthracycline class of anticancer agents and was originally discovered as a pink/red complex with DNA and RNA and named SN-07. The chromophore was subsequently separated from the nucleic acids by nuclease digestion and …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides

Similar Documents

Publication Publication Date Title
Cutts et al. The power and potential of doxorubicin‐DNA adducts
US5874412A (en) Bis-anthracyclines with high activity against doxorubicin resistant tumors
Skladanowski et al. Interstrand DNA crosslinking induced by anthracyclines in tumour cells
Shavit et al. Covalently linked kanamycin–Ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance
US20030229028A1 (en) Methods and compositions for reducing side effects in chemotherapeutic treatments
US7557090B2 (en) Anthracycline antibiotics and methods of treating cancer using the same
M. Cutts et al. Potential therapeutic advantages of doxorubicin when activated by formaldehyde to function as a DNA adduct-forming agent
US5543514A (en) Water-soluble sapphyrins
Alsarraf et al. A dendritic β-galactosidase-responsive folate–monomethylauristatin E conjugate
US6437105B1 (en) Methods and compositions for the manufacture of highly potent anthracycline-based antitumor agents
Kimura et al. Barminomycin, a model for the development of new anthracyclines
Cutts et al. Structural requirements for the formation of anthracycline-DNA adducts
WO2006095636A1 (en) Novel compound selectively activated at target site and utilization of the same
Ueda et al. Section Review Oncologic, Endocrine & Metabolic: Recent developments with novel anthracyclines for the treatment of haematological malignancies
Kelso et al. Characterisation of anthracyclines from a cosmomycin D-producing species of Streptomyces by collisionally-activated dissociation and ion mobility mass spectrometry
Gmeiner et al. Preparation of Oligomeric 2′-Deoxy-5-Fluorouridylate of Defined Length and Backbone Composition: A Novel Pro-Drug Form of the Potent Anti-Cancer Drug 2′-Deoxy-5-Fluorouridylate
Rubio-Ruiz et al. Masking strategies for the bioorthogonal release of anticancer glycosides
AU717689C (en) Bis-anthracyclines with high activity against doxorubicin resistant tumors
Efimov et al. Cross-linked nucleic acids: formation, structure, and biological function
Mistry et al. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b
Bognanni et al. Cyclodextrin Dimers Functionalized with Biotin as Nanocapsules for Active Doxorubicin Delivery Against MCF‐7 Breast Cell Line
Todorova et al. Antitumor effect of new conjugates of anthracycline antibiotic carminomycin bound to chitosan
Penasse Synthesis of polyfunctional carbon-dots, a potential carrier for drug delivery
C. Ajithkumar et al. DNA-drug Conjugates for Site-specific Delivery in Anti-cancer Therapy
WO2005111056A1 (en) New esters of adenosine nucleosides and carboxylic acid